Test Price
2,800 AED✅ Home Collection Available
ATP1A2 Gene Alternating Hemiplegia of Childhood Type 1 Genetic Test in UAE | 2,800 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
Diagnostic Certainty:
99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified NGS Processing.
Home Collection:
Paid Hospital-Grade Cold-Chain Home Collection & VIP Mobile Phlebotomy, 8 AM – 11 PM daily.
Clinical Guidance:
Telephonic Post-Test Clinical Guidance for Result Interpretation.
Insurance Billing:
Direct Billing Verification via WhatsApp: +971 54 548 8731
Test Overview & Methodology
The ATP1A2 gene test employs comprehensive Next-Generation Sequencing (NGS) to screen all coding exons for pathogenic variants causing Alternating Hemiplegia of Childhood type 1 (AHC1). This definitive molecular analysis distinguishes AHC from mimicking epilepsies and directs targeted therapeutic interventions.
| Feature | Our Test (NGS) | Closest Alternative |
|---|---|---|
| Methodology | Next-Generation Sequencing (NGS) with high coverage of all ATP1A2 coding regions | Sanger sequencing of selected exons only |
| Variant Detection | Single nucleotide variants, small indels, copy number changes | Point mutations and small indels in targeted regions |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| Clinical Utility | Confirmation of AHC1, family risk assessment, pre‑implantation genetic diagnosis | Limited diagnostic scope, may miss deep intronic or regulatory variants |
Physician Insight & Safety Protocols
“I understand the profound anxiety parents face when their child presents with recurrent hemiplegic episodes. This NGS‑based ATP1A2 analysis is the most sensitive diagnostic tool we have to confirm Alternating Hemiplegia of Childhood type 1, allowing us to move beyond symptomatic management toward targeted therapy and informed genetic counseling. Please remember that every genetic variant must be interpreted within the full clinical picture, and I encourage you to discuss these results in detail with your neurologist or medical geneticist.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
⚠️ Important: Do Not Discontinue Medication Without Consultation
Do not discontinue any prescribed medication without consulting your doctor. Abrupt changes may precipitate severe neurological crises. Always follow the treatment plan established by your neurologist.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria & Emergency Red Flags
- Exclusion: The test is not suitable for asymptomatic individuals without clinical suspicion of AHC or without a pre‑test genetic counseling session (required to draw a full pedigree).
- Minors: In accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability, a parent or legal guardian must provide written informed consent for patients under 18 years.
- Emergency Red Flags: If the patient experiences prolonged unilateral/bilateral paralysis lasting >24 hours, status epilepticus, or respiratory distress, seek immediate emergency medical attention at the nearest licensed facility.
- Data Privacy: All genetic data is protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring end‑to‑end encryption and secure reporting to your referring physician.
Patient FAQ & Clinical Guidance
1. Why is the ATP1A2 gene test important for my child’s alternating hemiplegia?
This test definitively identifies pathogenic ATP1A2 mutations, confirming AHC type 1 with high specificity, thereby enabling targeted therapies and informed genetic counseling for your family.
2. How should I prepare for the test and what sample is required?
A simple blood draw is collected at home via our VIP Mobile Phlebotomy service. A mandatory genetic counseling session and pedigree chart must be completed beforehand to ensure accurate interpretation.
3. How long until results are delivered, and are they confidential?
Results are available in 3 to 4 weeks and are encrypted and delivered directly to your neurologist, fully compliant with UAE PDPL and Federal Law No. 2 of 2019 on health information and communication technology.
UAE Regulatory & Data Privacy Adherence
Data Protection & Compliance
All genetic testing and patient data are handled in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your results are encrypted and shared only with authorised physicians. DNA Labs UAE is DHA-licensed (License No. 1143) and adheres to the highest standards of medical confidentiality.
Clinical & Logistical Metadata
| Test Name | ATP1A2 Gene Alternating Hemiplegia of Childhood Type 1 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA) – VIP Mobile Phlebotomy available daily 8 AM – 11 PM |
| Methodology Used | Next-Generation Sequencing (NGS) of ATP1A2 gene coding regions |
| ICD-10-CM Code | G24.8 |
| LOINC Code | 94536-9 |
| DHA Facility License & Laboratory Address Invariants | DHA Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians